Ignite Creation Date:
2024-05-06 @ 2:42 AM
Last Modification Date:
2024-10-26 @ 11:22 AM
Study NCT ID:
NCT02102672
Status:
UNKNOWN
Last Update Posted:
2014-04-03
First Post:
2014-03-31
Brief Title:
Trimetazidine in Pulmonary Artery Hypertension
Sponsor:
Pontificia Universidad Catolica de Chile
Organization:
Pontificia Universidad Catolica de Chile
Study Overview
Official Title:
Comprehensive Evaluation of Right Ventricular Function Ventricular Remodeling and Micro RNA Profiling in Pulmonary Artery Hypertension Effects of a Fatty Acid Oxidation Inhibitor
Status:
UNKNOWN
Status Verified Date:
2014-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary artery hypertension PAH is a chronic and progressive disease that affects 15 persons per million Although current therapy has improve disease prognosis PAH still has a poor survival with a median survival of 28 years after diagnosis In the last few years new key elements in PAH pathogenesis have been discovered such as the role of metabolism in disease onset and progression In fact PAH pulmonary smooth muscle cells switch into a glycolytic phenotype which resembles the metabolism of cancer cells The investigators hypothesis is that fatty acid oxidation inhibition reverts the PAH adverse phenotype by restoring mitochondrial function and morphology decreasing proliferation and restoring apoptosis susceptibility in pulmonary smooth muscle cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None